NVP-LCQ195

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406789

CAS#: 902156-99-4

Description: NVP-LCQ195; also known as LCQ 195 and AT9311, is a potent inhibitor of cyclin-dependent kinases (CDKs). LCQ195 inhibits CDK1, CDK2 and CDK5, as well as CDK3 and CDK9. LCQ195 induced cell cycle arrest and eventual apoptotic cell death of MM cells, even at sub-μmol/l concentrations, spared non-malignant cells, and overcame the protection conferred to MM cells by stroma or cytokines of the bone marrow milieu. Cell cycle regulators, such as cyclin-dependent kinases (CDKs), are appealing targets for multiple myeloma (MM) therapy given the increased proliferative rates of tumour cells in advanced versus early stages of MM.


Chemical Structure

img
NVP-LCQ195
CAS# 902156-99-4

Theoretical Analysis

MedKoo Cat#: 406789
Name: NVP-LCQ195
CAS#: 902156-99-4
Chemical Formula: C17H19Cl2N5O4S
Exact Mass: 459.05
Molecular Weight: 460.330
Elemental Analysis: C, 44.36; H, 4.16; Cl, 15.40; N, 15.21; O, 13.90; S, 6.96

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: NVP-LCQ-195; NVP-LCQ 195; NVP-LCQ195. LCQ-195; LCQ 195; LCQ195; AT9311; AT-9311; AT 9311.

IUPAC/Chemical Name: 4-[(2,6-dichlorobenzoyl)amino]-N-(1-methylsulfonylpiperidin-4-yl)-1H-pyrazole-5-carboxamide

InChi Key: CCUXEBOOTMDSAM-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H19Cl2N5O4S/c1-29(27,28)24-7-5-10(6-8-24)21-17(26)15-13(9-20-23-15)22-16(25)14-11(18)3-2-4-12(14)19/h2-4,9-10H,5-8H2,1H3,(H,20,23)(H,21,26)(H,22,25)

SMILES Code: O=C(C1=C(NC(C2=C(Cl)C=CC=C2Cl)=O)C=NN1)NC3CCN(S(=O)(C)=O)CC3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 460.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: McMillin DW, Delmore J, Negri J, Buon L, Jacobs HM, Laubach J, Jakubikova J,
Ooi M, Hayden P, Schlossman R, Munshi NC, Lengauer C, Richardson PG, Anderson KC,
Mitsiades CS. Molecular and cellular effects of multi-targeted cyclin-dependent
kinase inhibition in myeloma: biological and clinical implications. Br J
Haematol. 2011 Feb;152(4):420-32. doi: 10.1111/j.1365-2141.2010.08427.x. Epub
2011 Jan 11. PubMed PMID: 21223249; PubMed Central PMCID: PMC4042406.